<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44307">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02529488</url>
  </required_header>
  <id_info>
    <org_study_id>ILH297-P002</org_study_id>
    <nct_id>NCT02529488</nct_id>
  </id_info>
  <brief_title>Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00</brief_title>
  <official_title>Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL Model TFNT00</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate visual outcomes and assess safety at 12 months
      (330-420 days) post bilateral implantation of the AcrySof® IQ PanOptix™
      Presbyopia-Correcting IOL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in regions where the test article is approved at the time of
      study start.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Binocular Defocus Visual Acuity (VA)</measure>
    <time_frame>Up to Day 120-180 from second eye implantation</time_frame>
    <description>Defocus VA (an indicator of the expected range of vision with a presbyopia-correcting IOL) will be tested binocularly (both eyes together) with the participant's best spectacle correction at a distance of 4 meters. Lenses of different spherical powers will be placed in front of the eyes to produce varying levels of defocus. The VA at each spherical power will be measured in logarithm of the minimum angle of resolution (logMAR), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. A lower numeric value represents better visual acuity.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>PanOptix IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL</intervention_name>
    <description>Multifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient</description>
    <arm_group_label>PanOptix IOL</arm_group_label>
    <other_name>Model TFNT00</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of bilateral cataracts with planned cataract removal by phacoemulsification
             with a clear cornea incision;

          -  Able to comprehend and willing to sign informed consent and complete all required
             postoperative follow-up procedures;

          -  Clear intraocular media other than cataract in both eyes;

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Clinically significant corneal abnormalities including corneal dystrophy,
             inflammation or edema;

          -  Ocular trauma, corneal transplant, retinal conditions, degenerative eye disorders, or
             color vision deficiencies;

          -  Glaucoma (uncontrolled or controlled with medication) or ocular hypertension;

          -  Pregnant or lactating;

          -  Expected to require ocular surgical or retinal laser treatment;

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr Clinical Manager, Cataract</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>August 19, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
